Lexaria Bioscience Warrant
LEXXW
LEXXW was delisted on the 13th of January, 2026.
5 hedge funds and large institutions have $125K invested in Lexaria Bioscience Warrant in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
68% less capital invested
Capital invested by funds: $389K → $125K (-$264K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$8.69K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$129 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$7.94K |
LEXXW Hedge Fund Activity: Q2 2023 in Review
5 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q2 2023, worth a combined $125K — down 68% from $389K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LEXXW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $8.69K. The largest seller was Sabby Management, cutting an estimated $7.94K.
- 5 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q2 2023, up from 3 in Q1 2023.
- Funds reported $125K of Lexaria Bioscience Warrant stock for Q2 2023, down 68% quarter-over-quarter.
- 2 funds opened new Lexaria Bioscience Warrant positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest Lexaria Bioscience Warrant buyer in Q2 2023 was Citadel Advisors, an estimated $8.69K added.
- The largest Lexaria Bioscience Warrant seller in Q2 2023 was Sabby Management, an estimated $7.94K sold.
Based on aggregated 13F filings for Q2 2023.